CPOCTP Certification Review

CPOCTP Certification Review

A Review Guide for the Certified Point-of-Care Testing Pharmacist (CPOCTP) Exam

A1c: Hemoglobin A1c

CLIA: Clinical Laboratory Improvement Amendments

CMS: Centers for Medicare & Medicaid

COLA: Commission on Office Laboratory Accreditation

CPA: Collaborative Practice Agreement

CPT: Current Procedural Terminology

CV: Coefficient of Variation

EHR: Electronic Health Record

HIPAA: Health Insurance Portability and Accountability Act

HIV: Human Immunodeficiency Virus

INR: International Normalized Ratio

KPI: Key Performance Indicator

NPV: Negative Predictive Value

OSHA: Occupational Safety and Health Administration

P&P: Policies and Procedures

PHI: Protected Health Information

POCT: Point-of-Care Testing

PPE: Personal Protective Equipment

PPM: Provider Performed Microscopy

PPV: Positive Predictive Value

QA: Quality Assurance

QC: Quality Control

SD: Standard Deviation

  • Definition: Medical diagnostic testing performed at or near the site of patient care. The goal is to provide immediate information to enable rapid clinical decision-making.
  • The Pharmacist's Role: The pharmacist can serve as the POCT director/coordinator, develop protocols, train staff, ensure quality, and/or perform testing and use the results to provide direct patient care (e.g., under a CPA).
  • Common Settings: Community pharmacies, ambulatory care clinics, physician offices, hospital units, and emergency departments.
  • Benefits of POCT: Includes improved patient access to testing, faster turnaround times for results, enhanced clinical decision-making, and improved patient engagement and outcomes.
  • Challenges of POCT: Includes the need for robust quality assurance programs, proper staff training and competency, and navigating the complex regulatory and reimbursement landscape.
  • CLIA (Clinical Laboratory Improvement Amendments of 1988): The key federal law that regulates all laboratory testing performed on humans in the U.S. All facilities performing testing must have a CLIA certificate.
  • CLIA Certificate of Waiver: The most common certificate for pharmacies performing POCT. It is required for sites that only perform tests designated by the FDA as "waived," meaning they are simple to perform and have a low risk of erroneous results.
  • CLIA Complexity Levels: Understanding the different levels: Waived, Provider Performed Microscopy (PPM), Moderate Complexity, and High Complexity. Each level has increasingly stringent requirements for personnel, quality control, and proficiency testing.
  • Accrediting Organizations: The role of CMS-approved accrediting bodies like COLA and The Joint Commission (TJC) in surveying and accrediting laboratories to ensure compliance with CLIA standards.
  • OSHA Regulations: Adherence to Occupational Safety and Health Administration standards for bloodborne pathogens, including having an exposure control plan and providing appropriate PPE.
  • State Law & BOP Regulations: Understanding that individual state laws and board of pharmacy regulations may have additional, stricter requirements for pharmacists performing and managing POCT.
  • QA vs. QC: Quality Assurance is the overall, systematic program to ensure the reliability of testing. Quality Control is the day-to-day testing of control materials to ensure the accuracy of a specific device or test kit.
  • External Quality Control (QC): The process of testing control materials (with known values) in the same manner as patient specimens. This must be done at a frequency defined by the manufacturer's instructions or facility policy (e.g., with each new lot, daily).
  • Internal/Electronic Controls: Built-in checks within the testing device that verify its electronic and operational integrity. These do NOT replace the need for external liquid QC.
  • Handling Out-of-Range QC: Having a clear protocol for when a QC result is out of range, which includes stopping all patient testing, investigating the cause, and documenting corrective actions before resuming testing.
  • Personnel Training & Competency Assessment: A critical component of QA. All personnel performing tests must have documented initial training and ongoing competency assessments (e.g., direct observation, testing a blind sample).
  • Proficiency Testing (PT): Required for moderate and high complexity labs (and a good practice for waived labs). Involves analyzing blind samples from an external agency to assess the accuracy of the entire testing process.
  • Patient Identification: The critical first step. Using at least two patient identifiers (e.g., name and date of birth) to ensure the right test is performed on the right patient.
  • Sample Types: Understanding the appropriate sample type for each test, such as capillary blood (fingerstick), nasal/pharyngeal swabs, saliva, or urine.
  • Proper Collection Technique: Adherence to the manufacturer's specific instructions for sample collection is essential to ensure an accurate result (e.g., correct site for fingerstick, proper technique for a nasal swab).
  • Pre-analytical Errors: Recognizing that the majority of lab errors occur in the pre-analytical phase. Common errors include improper sample collection, incorrect sample type, and inadequate sample volume.
  • Biohazard Waste Management: Following OSHA guidelines for the safe disposal of all patient-related waste, including used test strips, lancets, and swabs, in appropriate biohazard containers.
  • Diabetes Management: Using POCT for blood glucose and Hemoglobin A1c to provide real-time data for medication adjustments, often under a CPA.
  • Cardiovascular Risk Reduction: Using POCT for lipid panels (TC, LDL-C, HDL-C, TG) to screen for dyslipidemia and monitor the effectiveness of statin therapy.
  • Anticoagulation Management: Using POCT for International Normalized Ratio (INR) to manage warfarin therapy in an anticoagulation clinic setting.
  • Infectious Disease Management: Using POCT for Group A Streptococcus, Influenza A/B, COVID-19, and HIV to facilitate rapid diagnosis and initiation of appropriate therapy (e.g., antivirals) or referral.
  • The "Test and Treat" Model: A model where pharmacists, often under a CPA, can perform a POCT and, if the result is positive, prescribe the appropriate medication (e.g., oseltamivir for influenza).
  • The POCT Workflow: A standardized, step-by-step process: 1) Patient identification & consent, 2) Sample collection, 3) Performing the test, 4) Interpreting and documenting the result, 5) Communicating the result to the patient and provider, 6) Taking clinical action.
  • Documentation Requirements: Meticulous documentation is essential. This includes the patient's name, date/time of test, name of the test, the result, the name of the person performing the test, and all QC records.
  • Billing for POCT: Using specific CPT codes for each test performed. Reimbursement requires proper enrollment and credentialing with payers.
  • "Incident-to" Billing: A common mechanism for pharmacist reimbursement for the clinical management services associated with POCT, where services are billed under a collaborating physician's NPI.
  • Result Communication: Having a clear policy for communicating all test results, especially critical values, to the patient's primary care provider in a timely manner.

Diagnostic Test Performance

Sensitivity: The ability of a test to correctly identify patients WITH the disease. (TP / (TP + FN))
Specificity: The ability of a test to correctly identify patients WITHOUT the disease. (TN / (TN + FP))
Positive Predictive Value (PPV): The probability that a patient with a positive test result actually has the disease. (TP / (TP + FP))
Negative Predictive Value (NPV): The probability that a patient with a negative test result actually does not have the disease. (TN / (TN + FN))

Quality Control Statistics

Mean (Average): The sum of all QC values divided by the number of values.
Standard Deviation (SD): A measure of the variation or dispersion of the QC data points.
Coefficient of Variation (CV%): (SD / Mean) * 100. A measure of the relative variability of the data. A lower CV% indicates higher precision.

Clinical Treatment Targets

A1c: <7% for most adults with diabetes (ADA).
Blood Pressure: <130/80 mmHg (ACC/AHA).
INR: 2.0-3.0 for most indications (e.g., atrial fibrillation, VTE).

  • A Lab Test is a Prescription: The principle that a lab test should be treated with the same level of care and professionalism as a medication, as the results directly influence prescribing and patient care.
  • Quality and Accuracy are Non-Negotiable: The absolute commitment to a rigorous quality assurance program, because an inaccurate test result is worse than no result at all.
  • The Test is a Tool, Not the Endpoint: The understanding that the POCT result is not the end of the encounter; it is the beginning of a clinical decision-making and patient counseling process.
  • Expanding Access to Care: Recognizing that pharmacist-led POCT is a powerful way to expand access to essential health screenings and timely treatment, especially in underserved communities.
  • The Pharmacist as a Diagnostician and Manager: The evolution of the pharmacist's role from dispensing to actively participating in the diagnostic and management process.
  • Integration is Key to Success: The understanding that for POCT to be truly valuable, the results and subsequent actions must be fully integrated into the patient's overall care plan and communicated to the entire healthcare team.
Return to CPOCTP Certification Hub